European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Trial Profile

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2018

At a glance

  • Drugs Adavosertib (Primary) ; Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Everolimus (Primary) ; Irinotecan (Primary) ; Nivolumab (Primary) ; Olaparib (Primary) ; Ribociclib (Primary) ; Temozolomide (Primary) ; Topotecan (Primary) ; Vistusertib (Primary)
  • Indications Leukaemia; Tumours
  • Focus Adverse reactions; Proof of concept
  • Acronyms ESMART
  • Most Recent Events

    • 06 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top